Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.47 USD

201.47
3,293,458

-0.21 (-0.10%)

Updated Nov 6, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $147.75, marking a +0.04% move from the previous day.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

Looking for value stocks? Healthcare has been ignored over the last year.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.

Sejuti Banerjea headshot

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

JNJ Management expects relatively consistent growth for the rest of the year.

AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine

AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.

Zacks Investment Ideas feature highlights: Dollar Tree, AbbVie and Sysco

Dollar Tree, AbbVie and Sysco are part of Zacks Investment Ideas article.

Benjamin Rains headshot

3 Recession-Proof Stocks Up 10% in 2022 to Buy Right Now

Today, we dive into three stocks that are poised to beat inflation and rise above any possible recession. All three names appear worth buying for the second half of 2022 and might be up for consideration as buy-and-hold stocks...

Mark Vickery headshot

Top Analyst Reports for Pfizer, Raytheon Technologies & Diageo

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Raytheon Technologies Corporation (RTX), and Diageo plc (DEO).

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $153.23, moving +0.25% from the previous trading session.

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why

Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $153.93, moving +0.08% from the previous trading session.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.

Kinjel Shah headshot

Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention

With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

Style Box ETF report for FLQL

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $138.28 in the latest trading session, marking a -0.63% move from the prior day.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease

The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY.